All In Biotech

Drug Trial Radar · NCT06338657

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

A Window of Opportunity Study of Taxanes in Head and Neck Cancer

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Apr 1, 2024

Primary completion

Sep 3, 2025

Study completion Sep 9, 2025

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Mar 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • PEOX-based Polymer Encapsulated Paclitaxel FID-007Drug

    Given IV

  • Tumor ResectionProcedure

    Undergo surgical resection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the phenotypical and functional changes of different T cell subsets within the tumor microenvironment after treatment with FID-007Time frame: Baseline up to 30 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.